Abstract
Background The mainstay of oral anticoagulant therapy, warfarin sodium, crosses the placenta during pregnancy and may cause fetal complications. Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) do not cross the placenta and have demonstrated utility in the prevention and treatment of thrombosis during pregnancy. Objectives The purpose of this study was to review treatment strategy, indication, and maternal and fetal outcomes in anticoagulated pregnancies at Kaiser Permanente Colorado. Patients/Methods We identified 103 pregnancies in 93 mothers prescribed an anticoagulant during a pregnancy occurring between January 1, 1998 and March 31, 2005. Results The majority of patients were treated with UFH (89.3%). Indications for anticoagulation included venous thromboembolism (VTE) prophylaxis (53.4%), history of pregnancy loss (29.1%), acute VTE (16.5%), and history of cerebral vascular accident (CVA) (1.0%). There were no maternal deaths. Fetal demise occurred in 8 pregnancies (7.8%) at a median 14 weeks gestation (range 7–22 weeks). No fetal demise occurred in pregnancies treated for acute VTE or history of CVA. There were two occurrences of pulmonary embolism (1.9%) and two hemorrhagic events requiring transfusion (1.9%). Conclusions Maternal and fetal adverse events were infrequent in our population of anticoagulated pregnancies. UFH remains a viable option among more expensive LMWH products.
Similar content being viewed by others
References
Rey E, Kahn S, David M, Shrier I (2003) Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361:901–908
Kujovich J (2004) Thrombophilia and pregnancy complications. Am J Obstet Gynecol 191:412–424
Ginsberg J, Hirsh J, Turner C, Levine MN, Burrows R (1989) Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 61:197–203
Hall J, Paul R, Wilson K (1980) Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68:122–140
Wesseling J, Van Driel D, Heymans H, Rosendaal FR, Geven-Boere LM, Smrkovsky M, Touwen BC, Sauer PJ, Van der Veer E (2001) Coumarins during pregnancy: long term effects on growth and development in school age children. Thromb Haemost 85:609–613
Jacobsen A, Qvigstad E, Sandset P (2003) Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG 110:139–144
Hunt B, Gatten M, Khamashta M, Nelson-Piercy C, Almeida A (2003) Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinolysis 14:735–739
Ulander V, Lehtola A, Kaaja R (2003) Long-term outcome of deep venous thrombosis during pregnancy treated with unfractionated heparin or low molecular weight heparin. Thromb Res 111:239–242
Nelson-Piercy C, Letsky E, de Swiet M (1997) Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at risk. Am J Obstet Gynecol 176:1062–1068
Blanco-Molina A, Trujillo-Santos J, Criado J (2007) Venous thromboembolism during pregnancy or postpartum: findings from the RIETE registry. Thromb Haemost 97:186–190
Bates S, Greer I, Hirsh J, Ginsberg J (2004) Use of antithrombotic agents during pregnancy. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. CHEST 126:627S–644S
Copplestone J, Pavord S, Hunt B (2004) Anticoagulation in pregnancy: a survey of current practice. Br J Haemotol 124:123–125
Kearon C, Ginsberg J, Julian J, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, Mackinnon B, Hirsh J, Gent M (2006) Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296:935–942
Lockwood C (2002) Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 99:333–341
Brill-Edwards P, Ginsberg J, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz J, Robinson KS, Whittom R, Couture G (2000) Safety of withholding heparin in pregnant women with a history of venous thromboembolism. NEJM 343:1439–1444
Barbour L, Oja J, Schultz L (2004) A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 191:1024–1029
De Carolis S, Ferrazzani S, De Stefano V, Garofalo S, Fatigante G, Rossi E, Leone G, Caruso A (2006) Inherited thrombophilia: treatment during pregnancy. Fetal Diagn Ther 21:281–286
Kupferminc M, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, Eldor A (2001) Low-molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Pregnancy 20:34–44
Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, Giarratano A, Licata G (2003) Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 48:728–731
Gris J, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, Ripart-Niveu S, Tailland M, Dauzat M, Mares P (2004) Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 103:3695–3699
Rai R, Cohen H, Dave M, Regan L (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 314:253–257
Grandone E, Brancaccio V, Colaizzo D, Scianname N, Pavone G, Di Minno G, Margaglione M (2002) Preventing adverse obstetric outcomes in women with genetic thrombophilia. Fertil Steril 78:371–375
Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J (2000) Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost 83:693–697
Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L (1999) Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 106:102–107
Farquharson R, Quenby S, Greaves M (2002) Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 100:408–413
Folkeringa N, Brouwer JL, Kortweg F, Veeger NJ, Erwich JJ, Holm JP, van der Meer J (2007) Reduction of high fetal loss rate by anticoagulant treatment in antithrombin, protein C or protein S deficient women. Br J Heamatol 136:656–661
Matziolis G, Perka C, Disch A, Zippel H (2003) Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 73:370–379
Douketis J, Ginsberg J, Burrows R, Duku EK, Webber CE, Brill-Edwards P (1996) The effects of long-term heparin therapy during pregnancy on bone density. Thromb Haemost 75:254–257
Backos M, Rai R, Thomas E, Murphy M, Dore C, Regan L (1999) Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 14:2876–2880
Casele H, Haney E, James A, Rosene-Montella K, Carson M (2006) Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol 195:1109–1113
Pettila V, Leinonen P, Markkola A, Hillesmaa V, Kaaja R (2002) Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87:182–186
Dahlman T, Sjoberg H, Ringertz H (1994) Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 170:1315–1320
Barbour L, Kick S, Steiner J, LoVerde M, Heddleston L, Lear J, Baron A, Barton P (1994) A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862–869
Morris T, Castrejon S, Devendra G, Gamst A (2007) No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous throbosis with either low-molecular-weight heparin or unfractionated heparin. A meta-analysis. CHEST 132:1131–1139
Handeland GF, Abidgaard GF, Holm U, Arneses KE (1990) Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 39:107–112
Wolzt M, Weltermann A, Nieszpauer-Los M, Schneider B, Fassolt A, Lechner K, Eichler HG, Kyrle P (1995) Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb Haemost 73:439–443
Beng CJ. Berstad A. Talstad I (1991) Incomplete reversal of enoxaparin-induced bleeding by protamine sulfate. Haemostasis 21:155–160
Shojania A (2004) More one: is laboratory monitoring of low-molecular-weight heparin necessary? Thromb Haemost 2:2276–2277
Buller H, Agnelli G, Hull R, Hyers TM, Prins H, Raskob GE (2004) Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. CHEST 126:401S–428S
Kitchen S, Iampietro R, Woolley A, Preston F (1999) Anti Xa monitoring during treatment with low-molecular-weight heparin or danaparoid: inter-assay variability. Thromb Haemost 82:1289–1293
Acknowledgements
We would like to acknowledge the KPCO Pharmacy Dept. and its Executive Director, Dennis Helling, PharmD, for their support of this study. This study was funded entirely by Kaiser Permanente Colorado. This study partially was undertaken in fulfillment of the requirements for Suzanne Parker’s American Society of Health-Systems Pharmacy residency program.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clark, N.P., Delate, T., Witt, D.M. et al. A descriptive evaluation of unfractionated heparin use during pregnancy. J Thromb Thrombolysis 27, 267–273 (2009). https://doi.org/10.1007/s11239-008-0207-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-008-0207-0